✦ LIBER ✦
PCV68 POTENTIAL COST-EFFECTIVENESS OF A BIOMARKER TEST TO RECLASSIFY PATIENTS WITH AN INTERMEDIATE RISK BASED ON THE FRAMINGHAM RISK SCORE INTO A LOWER OR HIGHER CATEGORY TO OPTIMIZE STATIN THERAPY
✍ Scribed by LT Burgers; WK Redekop; JL Severens
- Book ID
- 118614605
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 79 KB
- Volume
- 13
- Category
- Article
- ISSN
- 1098-3015
No coin nor oath required. For personal study only.